immunetolerance.org
Site map | Immune Tolerance Network
https://www.immunetolerance.org/sitemap
BRI - Seattle Office. MGH - Bethesda Office. UCSF - San Francisco Office. The Immune Tolerance Network. And is sponsored by the National Institute of Allergy and Infectious Diseases. Part of the National Institutes of Health. 2016 Immune Tolerance Network.
immunetolerance.org
Achievements | Immune Tolerance Network
https://www.immunetolerance.org/about-us/achievements
Preventing Peanut Allergy in Young Children. The Immune Tolerance Network’s (ITN) Learning Early About Peanut (LEAP) study was the first randomized trial to prevent food allergy in a large cohort of high-risk infants. The results of the study, published in the New England Journal of Medicine. And available on TrialShare. Demonstrated that consumption of a peanut-containing snack by infants who were at high-risk for developing peanut allergy prevented the subsequent development of allergy. In the New Engl...
immunetolerance.org
Volunteering For A Clinical Trial | Immune Tolerance Network
https://www.immunetolerance.org/public/clinical-trial-info
Volunteering For A Clinical Trial. Every year, millions of people volunteer to take part in clinical trials. For some, it is an opportunity to help advance medical research. For others, it is a chance to gain access to latest potential treatment. For everyone, however, it is a very personal decision and one that requires careful thought. Below is a list of online resources that will help you decide whether participation in a clinical trial is the right decision for you. Your Rights and Informed Consent.
immunetolerance.org
Mission & Values | Immune Tolerance Network
https://www.immunetolerance.org/professionals/about-us/our-mission-values
The Immune Tolerance Network (ITN) is an organization born from the collective vision of the National Institute of Allergy and Infectious Disease (of the National Institutes of Health) and the tolerance research community. As such, our vision and the principles upon which we were founded are a reflection of the community itself. To advance the clinical application of immune tolerance by performing high quality clinical trials of emerging therapeutics integrated with mechanism-based research. We are built...
immunetolerance.org
Accessibility Statement | Immune Tolerance Network
https://www.immunetolerance.org/accessibility
The Immune Tolerance Network and its sponsors are committed to providing access to our web pages for individuals with disabilities. To meet this commitment, this site complies with the requirements of Section 508 of the Rehabilitation Act. For assistance. To enable us to respond in a manner most helpful to you, please indicate the nature of your accessibility problem, the preferred format in which you wish to receive the material, the web address of the requested material, and your contact information.
immunetolerance.org
About Us | Immune Tolerance Network
https://www.immunetolerance.org/professionals/about-us
The Immune Tolerance Network (ITN) is a collaborative network for clinical research, funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Our mission is to accelerate the clinical development of immune tolerance therapies. ITN by the numbers. 60 total clinical trials - 13 Allergy trials; 27 Autoimmunity trials; 20 Transplant trials. 250 clinical sites and investigators at leading academic hospitals worldwide. Of highly respected faculty from inst...
immunetolerance.org
ITN Opens the EXTEND Study in Type 1 Diabetes | Immune Tolerance Network
https://www.immunetolerance.org/news/2015/01/itn-opens-extend-study-type-1-diabetes
ITN Opens the EXTEND Study in Type 1 Diabetes. January 30, 2015 -. A new ITN type 1 diabetes trial opened today at the first site, Sanford Health in Sioux Falls, SD. The. Trial (Preserving Beta-Cell Function with Tocilizumab in New Onset Type 1 Diabetes) will test whether tocilizumab (ACTEMRA ; Genentech), an antibody that targets the interleukin-6 (IL-6) receptor, can slow disease progression and help maintain natural insulin production in adults with new-onset type 1 diabetes.
immunetolerance.org
Alefacept Preserves Beta Cell Function in Some New-Onset Type 1 Diabetes Patients Out to Two Years | Immune Tolerance Network
https://www.immunetolerance.org/news/2015/07/alefacept-preserves-beta-cell-function-some-new-onset-type-1-diabetes-patients-out-two-
Alefacept Preserves Beta Cell Function in Some New-Onset Type 1 Diabetes Patients Out to Two Years. July 20, 2015 -. Journal of Clinical Investigation. Analyses from blood samples collected from T1DAL participants revealed that alefacept selectively reduced certain populations of memory T cells that lead to inflammatory effects while sparing the protective, regulatory T cells. This favorable balance between regulatory and inflammatory T cell subsets may be part of the mechanism underlying the observe...
immunetolerance.org
Clinical Trials | Immune Tolerance Network
https://www.immunetolerance.org/public/clinical-trial-info/active-trials
The ITN conducts clinical trials with the goal of achieving immune tolerance for patients. To see a list of ITN's clinical trials that are. Please select a disease area:. To see all of ITN's active and completed studies, please visit. T1D Extended Study (T1DES). Linda DiMeglio, MD, MPH, Indiana University and Riley Hospital for Children, Indianapolis, IN. T1DES is a clinical study for people with type 1 diabetes who were previously enrolled in an ITN clinical study. Allograft Tolerance Study (ALLTOL).
immunetolerance.org
Support | Immune Tolerance Network
https://www.immunetolerance.org/professionals/about-us/our-sponsors
The Immune Tolerance Network (ITN) is the product of several years of planning by the National Institutes of Health (NIH) and the extramural research community. We are grateful for the effort and insight of our sponsors, who continue to support the mission of the Network. National Institute of Allergy and Infectious Diseases. JDRF also sponsors the ITN's Type 1 Diabetes Preclinical Consortium, an initiative to generate preclinical data to support combination therapy studies in type 1 diabetes. The co...
